Biotech: Page 11
-
Retrieved from National Cancer Institute on September 27, 2019
BridgeBio oncology spinout to go public in blank-check merger
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.
By Ben Fidler • Feb. 28, 2025 -
Daniel Tadevosyan via Getty Images
Praxis hits trial setback; Bristol Myers lays off staff in New Jersey
The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.
By BioPharma Dive staff • Feb. 28, 2025 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Courtesy of Vertex Pharmaceuticals
Gene editingVertex ends gene editing research pact with Verve
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.”
By Kristin Jensen • Feb. 27, 2025 -
Daniel Tadevosyan via Getty Images
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.
By BioPharma Dive staff • Feb. 26, 2025 -
Permission granted by Eikon Therapeutics
Startup launchesEikon raises $351M in one of the year’s largest biotech venture rounds
The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs.
By Gwendolyn Wu • Feb. 26, 2025 -
Grandbrothers via Getty Images
‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts
The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, investors said.
By Gwendolyn Wu • Feb. 25, 2025 -
Permission granted by ICON
Sponsored by ICONPartnering for success in early phase clinical development
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.
Feb. 24, 2025 -
Daniel Tadevosyan via Getty Images
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.
By BioPharma Dive staff • Updated Feb. 24, 2025 -
Permission granted by Bluebird bio
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth.
By Ben Fidler • Feb. 21, 2025 -
Permission granted by BridgeBio Pharma
BridgeBio’s heart drug launch gets off to a fast start
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more than doubled since January and outpaced investor expectations.
By Ben Fidler • Feb. 20, 2025 -
Daniel Tadevosyan via Getty Images
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Ultragenyx secured a PDUFA date for its Sanfilippo gene therapy.
By BioPharma Dive staff • Feb. 19, 2025 -
Courtesy of Recursion Pharmaceuticals
Recursion CEO launches pre-seed fund in response to NIH cuts
Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.
By Gwendolyn Wu • Feb. 19, 2025 -
Spencer Platt via Getty Images
Emerging biotech‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public
The heads of three early-stage companies shared lessons from going public in a challenging market for biotech stocks.
By Jacob Bell • Feb. 14, 2025 -
Daniel Tadevosyan via Getty Images
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.
By BioPharma Dive staff • Feb. 13, 2025 -
koto_feja via Getty Images
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.
By Jacob Bell • Feb. 13, 2025 -
Michael M. Santiago via Getty Images
IPO windowAardvark prices $94M IPO to fund Prader-Willi, obesity drug work
Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, potentially, more common obesity-related conditions.
By Ben Fidler • Feb. 12, 2025 -
Permission granted by Biogen
Biogen inks royalty deal to gain funding for lupus drug R&D
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.
By Kristin Jensen • Feb. 12, 2025 -
Daniel Tadevosyan via Getty Images
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.
By BioPharma Dive staff • Feb. 11, 2025 -
Courtesy of Vertex Pharmaceuticals
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.
By Ned Pagliarulo • Feb. 10, 2025 -
Oonal via Getty Images
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
By Ned Pagliarulo • Feb. 10, 2025 -
magicmine, iStock / Getty Images Plus via Getty Images
Pliant shares collapse as company halts fibrosis drug study
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, but doesn’t yet know what led to their decision.
By Ben Fidler • Feb. 10, 2025 -
Daniel Tadevosyan via Getty Images
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.
By BioPharma Dive staff • Feb. 7, 2025 -
Pla2Na via Getty Images
Immune drugmakers Alumis and Acelyrin to merge
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing.
By Gwendolyn Wu • Feb. 7, 2025 -
Permission granted by Sionna Therapeutics
IPO windowVertex challenger Sionna prices $191M IPO
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.
By Gwendolyn Wu • Feb. 6, 2025 -
Daniel Tadevosyan via Getty Images
Amgen obesity drug on hold; Regeneron sets first dividend
Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”
By Ned Pagliarulo • Feb. 5, 2025
Previous
